 "Indoco Remedies surges on USFDA nod for Goa facility")
Indoco Remedies has moved higher by 15% to Rs 305 on the BSE after the pharmaceutical company announced that it has received US regulator nod for its manufacturing facility in Goa.
“The company has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its sterile and solid dosages facility (Goa Plant II) situated at L-32/33/34 Verna Industrial Estate, Goa,” Indoco Remedies said in a statement.
This approval confirms the closure of inspection conducted in July'2015, it added.
At 02:34 am, the stock was up 13% at Rs 297 on the BSE on back of heavy volumes. A combined 409,782 shares changed hands on the BSE and NSE compared to an average sub 50,000 shares that were traded daily in past two weeks.
“The company has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its sterile and solid dosages facility (Goa Plant II) situated at L-32/33/34 Verna Industrial Estate, Goa,” Indoco Remedies said in a statement.
This approval confirms the closure of inspection conducted in July'2015, it added.
At 02:34 am, the stock was up 13% at Rs 297 on the BSE on back of heavy volumes. A combined 409,782 shares changed hands on the BSE and NSE compared to an average sub 50,000 shares that were traded daily in past two weeks.
